This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The looming threat is the pending patentapplications by Gilead in India. A Look at the Pre-Grant Oppositions Gilead has multiple patentapplications for Lenacapavir in India, including those seeking patents on its choline and sodium salts. and the oppositions raised against these applications.
Striking the middle ground between satisfying the strict basis requirement in Europe and avoiding patent profanity in the US, renders the decision of when to file a patentapplication all the more critical. The SPC on the composition of matter case for secukinumab expires in 2030.
IP: Tool for Promotion of Innovation The UN’s 2030 Agenda for Sustainable Development, adopted in 2015, aims to promote global sustainable development but often excludes intellectual property (IPR) due to the challenges in establishing standards and practical meaning.
The issue here pertains to the question of whether a patent office located in one place can transfer a patentapplication to another office in the absence of any specific provision in the law. India aims to grow pharma sector by four times to USD 200 Billion by 2030.
1 For example, Ford and BMW announced in May 2021 that they had invested $130m in solid-state battery start-up Solid Power to deliver batteries that will be deployed in EVs by 2030. One key strategic consideration in building a robust patent portfolio involves deciding in which countries to file patentapplications.
7 And with President Joe Biden’s recent executive order setting a target for zero-emissions vehicles to account for half of all automobiles sold in the United States by 2030, solid-state battery development likely will kick into even higher gear over the course of the decade. Policy Considerations.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content